A survey on intensity of statin therapy among diabetes mellitus patients in secondary care practice



To assess the prevalence of statin usage, intensity of statin therapy, and serum LDL cholesterol levels achieved in clinical diabetes mellitus population to analyze whether the recommendations of American College of Cardiology/American Heart Association’s cholesterol guidelines 2013 (ACC/AHA cholesterol guidelines 2013) are achieved in them.


Fasting lipid profile values, prevalence of statin usage, and intensity of statin therapy among 306 diabetes mellitus patients in the age group of 40 to 75 years, visiting the medicine department of a secondary care hospital, were noted. Results were analyzed as per the ACC/AHA cholesterol guidelines 2013 using Microsoft excel 2016.


Out of 294 diabetes mellitus patients who qualified for statin therapy, only 68% (199) are on statins. In this group of patients, 22% (44) are on low-intensity, 77% on moderate-intensity, and 1% (3) are on high-intensity statin therapy. When the serum LDL cholesterol levels of the diabetic patients were analyzed, only 21% (64) of them could achieve the level of < 70 mg/dl, below which the risk of developing cardiovascular disease is low.


Dyslipidemia, a risk factor for the development and progression of atherosclerosis among diabetes mellitus patients, is not being treated in secondary care practice as per the ACC/AHA cholesterol guidelines of 2013. Initiating moderate-intensity statin therapy among non-statin users and shifting patients on low-intensity to moderate-intensity statin therapy would help these patients in achieving the desired serum LDL cholesterol level of < 70 mg/dl.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32:280–99.

    CAS  Article  Google Scholar 

  2. 2.

    Gerstein HC, Miller ME, et al. Action to control cardiovascular risk in diabetes study group effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.

    CAS  Article  Google Scholar 

  3. 3.

    Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10(6):684–6.

    CAS  Article  Google Scholar 

  4. 4.

    Rydén L, Standl E, Bartnik M, van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular disease of the European Society of Cardiology (ESC) and of the European Association for the Study of diabetes (EASD). Eur Heart J. 2007;28:88–136.

    Article  Google Scholar 

  5. 5.

    Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet. 2008;371(9607):117–25.

    CAS  Article  Google Scholar 

  6. 6.

    Stossel TO. The discovery of statins. Cell. 2008;134:903–5.

    Article  Google Scholar 

  7. 7.

    Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–8.

    CAS  Article  Google Scholar 

  8. 8.

    Cowie CC, Howard BV, Harris MI. Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population. Circulation. 1994;90(3):1185–93.

    CAS  Article  Google Scholar 

  9. 9.

    Austin MA, Edwards KL. Small dense low density lipoproteins, the insulin resistance syndrome, and non-insulin dependent diabetes. Curr Opin Lipidol. 1996;7(3):167–71.

    CAS  Article  Google Scholar 

  10. 10.

    Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109:III2–7.

    Article  Google Scholar 

  11. 11.

    Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study. Arterioscler Thromb Vasc Biol. 2000;20(3):830–5.

    CAS  Article  Google Scholar 

  12. 12.

    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.

    Article  Google Scholar 

  13. 13.

    Lambert M. ACC/AHA release updated guideline on the treatment of blood cholesterol to reduce ASCVD risk. Am Fam Physician. 2014;90:260–5.

    Google Scholar 

  14. 14.

    Stone NJ, Robinson JG, Lichtenstein AH. ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;63(25 Pt B):2889–934.

    PubMed  Google Scholar 

  15. 15.

    Steen DL, Khan I, Becker L, et al. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: insights from a large US managed-care population. Clin Cardiol. 2017;40:155–62.

    Article  Google Scholar 

  16. 16.

    Marz W, Dippel FW, Theobald K, et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: real-world evidence from Germany. Atherosclerosis. 2018;268:99–107.

    Article  Google Scholar 

  17. 17.

    Teramoto T, Uno K, Miyoshi I, et al. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis. 2016;251:248–54.

    CAS  Article  Google Scholar 

  18. 18.

    Nayor M, Vasan RS. Recent update to the use cholesterol treatment guidelines: a comparison with international guidelines. Circulation. 2016;133(18):1795–806.

    CAS  Article  Google Scholar 

  19. 19.

    Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

    Article  Google Scholar 

  20. 20.

    Bandyopadhyay D, Qureshi A, Ghosh S, et al. Safety and efficacy of extremely low LDL-cholesterol levels and its prospects in hyperlipidemia management. Journal of Lipids. 2018. https://doi.org/10.1155/2018/8598054.

  21. 21.

    Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J of Lipid Res. 2009;50:S172–7.

    Article  Google Scholar 

  22. 22.

    2018 guideline on the management of blood cholesterol. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiology 2019; e285-e350 DOI: https://doi.org/10.1016/j.jacc.2018.11.003.

Download references

Author information



Corresponding author

Correspondence to K. Indira Adiga.

Ethics declarations

This study was approved by the hospital ethics committee (IEC Project No: 422/2015) of the university.

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Adiga, K.I., Padmakumar, R. & Shashikiran, U. A survey on intensity of statin therapy among diabetes mellitus patients in secondary care practice. Int J Diabetes Dev Ctries (2020). https://doi.org/10.1007/s13410-020-00822-7

Download citation


  • ACC/AHA cholesterol guidelines 2013
  • Diabetes mellitus
  • Intensity of statin therapy
  • Serum LDL cholesterol level